RESUMEN
A Tempol compound with an amine group (4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl, NH2-Tempol) was cross-linked to hemoglobin in a one-step polymerization reaction to produce a novel hemoglobin-based oxygen carrier (HBOC) designated PolyHb-Tempol. The reaction parameters, including the reaction time, pH, temperature, and ratio of reactants, were optimized, and the physiochemical properties of the resulting product were characterized. PolyHb-Tempol didn't show any toxicity towards endothelial cells. Furthermore, from observations of cell morphology and viability, PolyHb-Tempol showed a significant ability to inhibit or eliminate oxidative stress induced by superoxide free radicals. These results suggest that PolyHb-Tempol may potentially be suitable as an HBOC.
Asunto(s)
Óxidos N-Cíclicos/química , Células Endoteliales/efectos de los fármacos , Glutaral/química , Hemoglobinas/farmacología , Estrés Oxidativo/efectos de los fármacos , Superóxido Dismutasa/metabolismo , Superóxidos/farmacología , Supervivencia Celular/efectos de los fármacos , Células Endoteliales/citología , Células Endoteliales/metabolismo , Hemoglobinas/química , Concentración de Iones de Hidrógeno , Cinética , Polimerizacion , Marcadores de Spin , TemperaturaRESUMEN
BACKGROUND: Patients with preeclampsia have higher circulating asymmetric dimethylarginine (ADMA). However, whether circulating ADMA is elevated before the diagnosis of preeclampsia has not been determined. METHODS: A meta-analysis of observational studies that reported circulating ADMA level before the onset of preeclampsia was performed. Pubmed and Embase were searched. Standardized mean differences (SMD) with 95% confidence intervals (CI) were used to estimate the differences in circulating ADMA. A random effect model or a fixed effect model was applied depending on the heterogeneity. The predictive efficacy of circulating ADMA for the incidence of preeclampsia was also explored. RESULTS: Eleven comparisons with 1338 pregnant women were included. The pooled results showed that the circulating ADMA was significantly higher in women who subsequently developed preeclampsia as compared with those did not (SMD: 0.71, p < 0.001) with a moderate heterogeneity (I2 = 43%). Stratified analyses suggested elevation of circulating ADMA is more remarkable in studies with GA of ADMA sampling ≥ 20 weeks (SMD: 0.89, p < 0.01) as compared those with GA of ADMA sampling < 20 weeks (SMD: 0.56, p < 0.01; p for subgroup interaction = 0.03). Differences of maternal age, study design, and ADMA measurement methods did not significantly affect the results. Only two studies evaluated the potential predicting ability of circulating ADMA for subsequent preeclampsia, and retrieved moderate predictive efficacy. CONCLUSIONS: Circulating ADMA is elevated before the development of preeclampsia. Studies are needed to evaluate the predictive efficacy of ADMA for the incidence of preeclampsia.
Asunto(s)
Arginina/análogos & derivados , Preeclampsia/sangre , Preeclampsia/diagnóstico , Arginina/sangre , Biomarcadores , Estudios de Casos y Controles , Femenino , Humanos , Incidencia , Preeclampsia/epidemiología , Embarazo , Pronóstico , Reproducibilidad de los Resultados , RiesgoRESUMEN
BACKGROUND: Biological and epidemiologic evidence suggested that androgen and its receptor may play an important role in ovarian carcinogenesis. However, results of previous association studies about ovarian cancer and AR CAG repeat polymorphism were inconsistent. Furthermore, none of these studies were conducted in Asians. METHODS: We evaluated the relationship between AR CAG repeat length and epithelial ovarian cancer (EOC) risk among a Chinese population including 1800 pathologically confirmed EOC patients and 1800 frequency matched controls. RESULTS: Women with longer AR CAG repeats had a decreased EOC risk (OR=0.87 for per CAG_A increase, 95% CI: 0.81-0.95). Compared to those with shorter (<22) CAG_A repeat length, women with of longer (≥22) CAG_A repeats had a 34% decreased EOC risk (OR=0.66, 95% CI: 0.57-0.75). For CAG_S and CAG_L, the results remained consistent. CONCLUSIONS: Our findings suggest that androgen signaling contributes to the development of ovarian cancer.
Asunto(s)
Pueblo Asiatico/genética , Neoplasias Glandulares y Epiteliales/genética , Neoplasias Ováricas/genética , Receptores Androgénicos/genética , Expansión de Repetición de Trinucleótido , Adulto , Carcinoma Epitelial de Ovario , China , Femenino , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Humanos , Persona de Mediana Edad , Neoplasias Glandulares y Epiteliales/patología , Neoplasias Ováricas/patologíaRESUMEN
Accumulating evidence has emerged important roles for microRNAs (miRNAs) participating in oncogenesis and growth of various cancers. We hypothesized that miR-661 played an important role in cell growth of ovarian cancer. Here, we found miR-661 was upregulated in human ovarian cancer cell lines and clinical tumor tissues. Our results revealed that miR-661 directly targeted INPP5J, thereby acting as tumor promoter in ovarian cancer cells by blocking cell proliferation. Importantly, we identified miR-661 as a positive regulator of INPP5J-induced AKT pathway. Taken together, our study sheds light onto the role of miR-661 as tumor promoter by targeting the INPP5J gene, and then promoting cell proliferation of ovarian cancer.